GlassScriptPhysician profile
Olivia Francis
NPI 1386006203
$1,520.77
in general payments reported to CMS, 2019-2025
14 companies · $515 in 2025
The $515 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2023: $592 · 2024: $59.91 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092 · Consulting Fee: $74.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.72 |
| Consulting Fee | $74.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.76 | 2023-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $226.85 | 2019-2024 | Nucala, Arexvy |
| Csl Behring | $225.03 | 2019-2025 | Hizentra, Andembry |
| Pfizer INC. | $137.59 | 2019-2025 | |
| Genzyme Corporation | $127.97 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $115.12 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $114.69 | 2023-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $107.63 | 2023-2025 | Cuvitru, Eohilia |
| Adma Biomanufacturing LLC | $74.55 | 2025 | |
| Grifols USA, LLC | $44.55 | 2023 | Xembify |
| Greer Laboratories, INC. | $24.42 | 2024 | Palforzia |
| Lilly USA, LLC | $21.45 | 2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $20.16 | 2025 | Nemluvio |
| Gc Biopharma USA, INC. | $17.00 | 2025 | Alyglo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.